BMO Capital Starts Nightstar Therapeutics (NITE) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Equities close higher as softer jobs data quiets rate-hike expectations
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Wedbush Starts Nightstar Therapeutics (NITE) at Outperform
October 23, 2017 6:17 AM EDTWedbush initiates coverage on Nightstar Therapeutics (NASDAQ: NITE) with a Outperform rating and a price target of $29.00.
Analyst David Nierengarten views shares as undervalued, given NITEs lead asset, NSR-REP1, is set to enter Ph 3 with curative potential for choroideremia (CHM), a rare... More
UPDATE: Leerink Partners Starts Nightstar Therapeutics (NITE) at Outperform
October 23, 2017 6:13 AM EDT(Updated - October 23, 2017 7:45 AM EDT)
(updated to expand analyst comment)
Leerink Partners initiates coverage on Nightstar Therapeutics (NASDAQ: NITE) with a Outperform rating and a price target of $25.00.
Analyst Joseph Schwartz called it a 'White Night' for Retinal Dystrophies. The... More
Jefferies Starts Nightstar Therapeutics (NITE) at Buy
October 23, 2017 3:13 AM EDTJefferies initiates coverage on Nightstar Therapeutics (NASDAQ: NITE) with a Buy rating and a price target of $25.00.
Analyst Michael Yee likes the pure-play profile and the company's differentiation through a sole focus on retinal diseases. The analyst believes the company pivotal Phase 3... More
